Alpha Tau Medical – Japan Shonin Approval and the 2026 Alpha DaRT Roadmap

1. Executive snapshot – why this approval matters

Alpha Tau Medical is trying to build an entire platform around one idea: using very short-range, high-energy alpha particles to burn tumors from inside the lesion, instead of bathing a large region of the body in external radiation. With the Japanese Ministry of Health, Labour and Welfare (MHLW) now granting full Shonin marketing approval for Alpha DaRT in unresectable, locally advanced or locally recurrent head and neck cancer, the company has just obtained its first real proof that regulators outside Israel are willing to treat this as a commercial therapy, not only an experimental one.

The approval is based on Japanese clinical data and follows a full-blown review by PMDA in the toughest device pathway Japan has. It is not a conditional authorization or a temporary compassionate scheme. At the same time, the label is restricted: only head and neck tumors that cannot be surgically removed or treated with standard radiation. Alpha Tau now has to run a post-market surveillance study in about 66 patients at five leading Japanese centers, both to reassure regulators and to build a clean real-world dataset which will be useful in future negotiations on reimbursement and label expansion.

In the U.S., the company is following a different regulatory route, anchored to the pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma (cSCC) and a modular PMA submission. That path, plus pilot studies in pancreatic cancer and glioblastoma, is what can turn a single-country head-and-neck approval into a real multi-indication platform over the 2026–2028 window.

2. Alpha DaRT – how the platform actually works

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is an intratumoral device approach. Instead of standard external radiotherapy, physicians insert small sources impregnated with radium-224 directly into the tumor. As radium decays, it releases short-lived daughter isotopes that travel only a few cell layers and emit alpha particles. The energy is very high, but the diffusion radius is tiny, which in theory allows a very localized destruction of tumor cells with limited damage to the surrounding normal tissue.

This is not a systemic radiopharmaceutical; patients are treated in a controlled environment, and the device is removed after treatment when the activity is no longer clinically relevant. The company’s early studies in Israel and Canada showed that, in indications such as skin squamous cell carcinoma and head and neck tumors, the local control rates could be high with acceptable toxicity. Those datasets form the basis for the approvals in Israel and now Japan and are part of the regulatory file being discussed with the FDA for U.S. indications.

From a platform point of view, Alpha Tau is trying to prove the same physics concept in progressively more complex tumors: superficial lesions (skin, head & neck), then deep internal organs such as pancreas and brain, where precise placement, safety, and the interaction with systemic therapies become critical.

3. Japan – first commercial authorization outside Israel

The Japanese Shonin decision is important for three reasons. First of all, it proves that a major regulator outside Israel has gone through the data, manufacturing and safety file and still decided to grant full marketing approval, not just an early access scheme. That approval covers unresectable, locally advanced or locally recurrent head and neck cancer – a group of patients that often exhaust surgery and standard radiotherapy and have limited systemic options.

Second, the approval is contingent on a structured post-market surveillance (PMS) plan: Alpha Tau will enroll 66 patients across five leading Japanese centers. These patients will be treated and followed under real-world conditions, with outcomes and safety systematically captured. For Alpha Tau, that PMS is not just an obligation; it becomes a strategic dataset for future label expansion and for discussions with Japanese payors around reimbursement levels.

Third, the Japanese physicians and societies that supported the file now become strong reference customers for the platform. The company and its Japanese partner HekaBio are positioning the launch as a “first-in-kind” alpha-emitting intratumoral therapy, something that can be later extended to other tumor types as data mature. In parallel, Alpha Tau expects to speak with PMDA about additional clinical studies in Japan, so this is unlikely to remain a single-indication story.

4. U.S. strategy – ReSTART pivotal trial and modular PMA

In the United States, Alpha Tau is not trying to copy the Japanese head-and-neck path. Instead, its centerpiece is the ReSTART trial in recurrent cutaneous squamous cell carcinoma, a pivotal, multi-center study which has already treated its first patients and is expected to complete enrollment around the first quarter of 2026. The trial evaluates Alpha DaRT in patients who have failed or are not candidates for surgery or standard radiotherapy and have very limited curative systemic options.

To accelerate review, the FDA has granted Alpha DaRT Breakthrough Device Designation in several indications and allowed a modular PMA pathway. Alpha Tau submitted the first PMA module, focused on non-clinical documentation, at the beginning of January 2026. The idea is to receive iterative feedback from the agency on manufacturing, preclinical and clinical packages rather than deliver a single, monolithic dossier at the very end of the program.

If enrollment in ReSTART is indeed completed in Q1 2026, the next 12–18 months could include both updated clinical data and additional PMA modules, setting up a potential marketing decision window once the full file is mature – though exact timing will depend entirely on FDA feedback and is inherently uncertain.

5. Internal organ tumors – pancreas and GBM as proof points

Beyond skin and head & neck, the most strategically important aspect of Alpha Tau’s program is its move into internal organs. Pancreatic cancer and recurrent glioblastoma are notoriously difficult indications, with dismal survival statistics and very few curative trajectories. If Alpha DaRT can show a reasonable safety profile and meaningful local control here, it would dramatically strengthen the case for the platform and for future combinations with systemic agents.

Pancreatic cancer – IMPACT study and ASCO GI data

In the United States, the company is running a pilot multi-center trial (IMPACT) in newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma, combining Alpha DaRT with chemotherapy. The first patient in this U.S. study was treated in September 2025, and Alpha Tau expects to complete patient accrual around the end of the first quarter of 2026, with initial data targeted by year-end 2026. This program builds on earlier Canadian and Israeli studies that have already been presented at scientific meetings, including the 2026 ASCO Gastrointestinal Cancers Symposium.

Recurrent glioblastoma – pilot study in the brain

On the brain side, the FDA granted Alpha Tau an Investigational Device Exemption (IDE) in 2025 to run a pilot study in recurrent glioblastoma. The first patient in this U.S. study was treated in December 2025 at the James Cancer Hospital at The Ohio State University – the first use of Alpha DaRT in the brain. The trial is small and primarily designed to evaluate safety and feasibility in a population that has already exhausted standard options and previously received CNS radiation.

Both programs are high-risk by definition. But if safety and signals of local control hold up, they will support the narrative that Alpha DaRT is not just a niche solution for superficial skin lesions, but a broader intratumoral platform that might later be combined with immunotherapy or other systemic agents.

6. Manufacturing and operations – New Hampshire facility

A key operational piece in the story is the manufacturing facility in New Hampshire. In October 2025, Alpha Tau obtained a radioactive material license for this site, which is described as the company’s first commercial-scale manufacturing facility. The license allows Alpha Tau to bring radioactive material on site and move from purely development-scale production to a setup designed for broader clinical and, eventually, commercial supply.

This facility is expected to support patients in the United States, Canada and other regions once Alpha DaRT is approved in those territories. In its Q3 2025 update and subsequent letter to shareholders, the company explicitly ties manufacturing ramp-up in New Hampshire to the anticipated “very active” clinical year in 2026 and to future commercial readiness, including for head & neck, pancreatic, GBM and other planned programs.

7. Financial position and funding risk

From a balance-sheet perspective, Alpha Tau is still very much a clinical-stage company: no meaningful product revenue and a cost base dominated by R&D and trial execution. As of September 30 2025, the company reported approximately 75.9 million U.S. dollars in cash, cash equivalents, short-term and restricted deposits, up from 62.9 million at the end of 2024. Over the first nine months of 2025, Alpha Tau generated a net loss of about 30.5 million dollars, with R&D expenses around 22.5 million dollars as clinical activity ramped up across multiple trials.

On that basis, and assuming that 2026 remains an “intense” year with five active trials plus manufacturing and commercial preparations, it is reasonable to expect that Alpha Tau will eventually need additional funding before the platform can be self-sustaining. The company itself warns about this in its SEC filings. Any future raise would depend on market conditions and the strength of the clinical and regulatory news flow.

8. 2026–2027 scenario map – how this could play out

This part is interpretive and scenario-based, not a forecast or a recommendation.

Looking forward, the combination of Japanese commercial entry and a cluster of 2026 clinical milestones makes Alpha Tau a binary, but structured, story. The company itself signals that 2026 should be “very active” from a clinical perspective, with enrollment completions and first data across several key trials. The way those data and regulatory interactions line up will determine whether investors start to see Alpha DaRT as a narrow, niche therapy or as a real platform.

For community members following DRTS, the point is not to treat any of these paths as “given”, but to understand what needs to go right – and in what order – for the Japanese approval to be the beginning of a broader commercial ramp rather than an isolated success.

9. Key risks and monitoring points

• Regulatory execution risk: FDA and other regulators may require more data, longer follow-up or additional studies before approving Alpha DaRT, even if ReSTART and other trials generate encouraging results.
• Commercial adoption in Japan: the Shonin decision is necessary but not sufficient. Real-world adoption will depend on reimbursement, training, and the willingness of oncologists to change habits.
• Technical complexity: intratumoral alpha devices demand precise placement and workflow integration. Any safety incidents or difficulties in real practice could slow uptake.
• Financing and dilution: if markets are weak when Alpha Tau needs additional capital, the cost of funding the platform could become a constraint, regardless of the science.
• Competition: other radiation-based or radiopharmaceutical approaches are moving forward in parallel; comparative data will matter once more options reach the clinic.

10. Bottom line for readers

The Japanese Shonin approval for Alpha DaRT in unresectable head and neck cancer is a real milestone for Alpha Tau Medical. It confirms that a major regulator has validated the concept and opened the door to commercial use in a high-need population. At the same time, the investment case remains dominated by what will happen in the United States and by the performance of trials in internal organ tumors.

Over the next 12–18 months, the story will be driven by: the quality of data from the ReSTART pivotal trial; the speed and tone of the modular PMA dialogue with the FDA; the early signals from pancreatic and GBM programs; the pace of Japanese uptake; and the company’s ability to fund operations without overly dilutive moves. For a community that has been following DRTS for months, this is the moment where the abstract Alpha DaRT concept starts to translate into concrete regulatory and commercial steps – but the binary nature of oncology device development has not gone away.